

*This email has been sent to all Vale of York GPs, Practice Managers and Practice Pharmacists*

Dear Colleagues

The CCG wants to commission the best treatments for local patients and wants the right clinician to have responsibility for those treatments. We want patients to have access to medicines which improve the quality of their care, that have demonstrated cost effectiveness and are safe.

Consideration of any drug's status is made at the Medicines Commissioning Committee which has doctor and pharmacist representatives from both Vale of York and Scarborough and Ryedale CCGs, York Hospital and both mental health providers.

Following discussion at the Medicines Commissioning Committee drugs are rated as red/amber/green/black:

- **'Green'** drugs are deemed suitable for primary or secondary care clinicians to prescribe.
- **'Amber specialist recommendation'** - secondary care/specialist recommended and deemed suitable for a GP to continue, with appropriate supporting documents, no written shared care agreement is required
- **'Amber specialist initiation'** – secondary care/specialist initiate and do required initial monitoring until deemed suitable for a GP to continue, with appropriate supporting documents, no written shared care agreement is required
- **'Amber shared care'** - requires initiation by a specialist, but with the potential to transfer to primary care, within written and agreed shared care frameworks, and according to the agreed process for transfer of care of those drugs. The relevant shared care guidance documents are available on the home page of the [joint formulary](#).
- **'Red'** drugs are deemed only appropriate for specialist prescribing and providers are funded to bear the costs of these drugs.
- **'Black'** drugs are deemed not appropriate for use locally by primary or secondary care clinicians. This is normally on the grounds of a lack of demonstrated cost effectiveness or safety.

For further information regarding how NHS Vale of York Clinical Commissioning Group commissions medicines please refer to the [Prescribing Policy for Primary Care Providers](#).

The CCG's Clinical Executive Team has accepted the recommendations from **November 2020** Medicines Commissioning Committee.

The full details of the recommendations for November 2020 are below.

Clinicians should note which drugs are not commissioned and therefore should not be recommended or prescribed for NHS patients within the Vale of York CCG.

The main changes to the commissioning position to highlight are listed below.

### **November 2020**

- The committee approved the addition of **Fiasp insulin prefilled flextouch pens** to the formulary alongside the 10ml vials and cartridges currently listed. These all remain as **AMBER SPECIALIST RECOMMENATION**.
- The committee reviewed the RAG status for **lacosamide** and **perampanel** and agreed to change from **AMBER SPECIALIST INITIATION** to **AMBER SPECIALIST RECOMMENDATION** as per all other anti-epileptics.
- Fibromyalgia was approved to add to the formulary as an unlicensed indication for **amitriptyline**, **nortriptyline** and **duloxetine** as per new RSS document for fibromyalgia.
- [NICE TA652](#), **alpelisib** with **fulvestrant** for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer was not approved and is **BLACK** on the formulary for this indication. NICE has terminated the appraisal as Novartis did not provide an evidence submission.

**The following NICE TA's are RED** – only to be prescribed by the relevant specialist:

- [NICE HST13](#): Volanesorsen for treating familial chylomicronaemia syndrome
- [NICE TA653](#): Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
- [NICE TA654](#): Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
- [NICE TA655](#): Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy

-----  
GP Practices are reminded to record **ALL red drugs** on the clinical system – instructions on how to do this are available [here](#).

[The Commissioning Position \(red amber green\)](#) list is being updated. Changes are being made to the joint formulary [www.yorkandscarboroughformulary.nhs.uk](http://www.yorkandscarboroughformulary.nhs.uk)

Yours sincerely,

The Medicines Optimisation Team

Please share this email with any GP locums who work for you. If they email their contact details to [Qasib Nazir](#) and we will add them to our database and include them in all future mailings.

For full minutes and recommendations please click [here](#)